BTIG adjusted the firm’s price target on Mersana Therapeutics (MRSN) to $17 from $6 and keeps a Buy rating on the shares after having updated the firm’s model to account for the company’s 1-for-25 reverse stock split and Q2 update. The firm expects the upcoming Emi-Le readout in the second half of 2025 will provide data for talks with the FDA to select a go-forward dose and discussion of the pivotal study design, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRSN:
- Promising Progress and Strategic Focus Drive Buy Rating for Mersana Therapeutics
- Mersana Therapeutics reports Q2 EPS ($4.87), consensus ($4.25)
- MRSN Upcoming Earnings Report: What to Expect?
- Upcoming Stock Splits This Week (July 28 to August 1) – Stay Invested
- Mersana Therapeutics trading halted, news pending